AVEO Pharmaceuticals, Inc.
Anti-NOTCH3 antibodies

Last updated:

Abstract:

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.

Status:
Grant
Type:

Utility

Filling date:

8 Jan 2018

Issue date:

18 Aug 2020